SYMLIN® (pramlintide acetate) injection is indicated as an adjunctive treatment in adults with type 1 or type 2 diabetes who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy.
For US Health Care Professionals|Go to Patient Site Register
US Health Care Professionals
Ajax error
JavaScript is required to access [Dynamic Service Title]
Please enable JavaScript in your browser settings.
Ajax error
AstraZeneca is committed to assisting appropriate patients with diabetes by offering savings and additional financial information on SYMLIN: